Tuesday, Xylem reported earnings per share of $1.12 from sales of $2.1 billion. Wall Street was looking for earnings per share of $1.08 from sales of $2.1 billion.
XYL heads into Q1 results with modest revenue and EPS growth expected, backed by infrastructure demand and acquisitions despite cost pressures.
CPC Advisors LLC acquired a new position in shares of Xylem Inc. (NYSE: XYL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,398 shares of the industrial products company's stock, valued at approximately $1,825,000. A number of other
Xylem (XYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Xylem Inc. (XYL) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Xylem (XYL) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Xylem (XYL) came out with quarterly earnings of $1.42 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.18 per share a year ago.
Beyond analysts' top-and-bottom-line estimates for Xylem (XYL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Xylem (XYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xylem (XYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
XYL gains from strong demand in metering, infrastructure and treatment markets, supported by acquisitions, project momentum and rising shareholder returns.